SERF1B Inhibitors
SERF1B inhibitors encompass a variety of compounds that interfere with different molecular pathways, thereby indirectly diminishing the activity of SERF1B. For instance, certain kinase inhibitors can disrupt phosphorylation events central to cellular signaling, which could lead to a reduction in SERF1B activity, considering its potential sensitivity to the phosphorylation status. Additionally, compounds targeting the PI3K/AKT/mTOR axis can attenuate the survival and metabolic signals that might be crucial for SERF1B's function or expression, thereby indirectly curtailing its activity. This could be a result of the protein's reliance on these pathways for its stability or regulatory control. In the same vein, inhibitors of the MAPK/ERK pathway, by diminishing downstream signaling, could similarly impact SERF1B activity if it falls within the scope of this signaling cascade's regulatory effects.
Further, inhibitors that modulate stress response pathways or affect cytoskeleton dynamics may also indirectly influence SERF1B activity. For example, by targeting p38 MAP kinase or JNK, these inhibitors can alter cellular responses to stress, potentially affecting SERF1B if it is regulated under such conditions. The same holds for inhibitors of ROCK, which by affecting cytoskeletal organization and cell motility, could have downstream effects on SERF1B function. Additionally, the disruption of protein transport or the inhibition of proteasome activity can lead to indirect effects on SERF1B, given the role of these processes in protein maturation and degradation. Proteasome inhibitors, for instance, could cause an accumulation of misfolded or damaged proteins, potentially stressing cellular systems that SERF1B is a part of or depends upon for its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that targets a wide range of kinases. By inhibiting these kinases, it may ultimately decrease the activity of SERF1B, which can be affected by phosphorylation events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3K). By blocking PI3K activity, it indirectly reduces the signaling that might be necessary for SERF1B functions related to cellular survival and metabolism. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK1/2, leading to reduced ERK pathway signaling. This pathway is involved in various cellular responses, and inhibition could thereby indirectly decrease SERF1B activity if it is downstream of this signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
A specific inhibitor of mTOR, which is central to cellular growth and metabolism. Inhibiting mTOR could reduce the overall protein synthesis and indirectly affect SERF1B activity if it relies on mTOR signaling for its function or stability. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that, by inhibiting PI3K, could indirectly lead to reduced SERF1B activity through the disruption of downstream signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAP kinase inhibitor which could indirectly influence SERF1B activity by altering stress response signaling pathways that may regulate SERF1B activity or expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A specific inhibitor of MEK, which could indirectly affect SERF1B by dampening the MAPK/ERK signaling pathway potentially involved in regulating SERF1B activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibitor of JNK, which may indirectly lead to decreased SERF1B activity by modifying the JNK signaling pathway that could be implicated in the regulation of SERF1B function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor that could indirectly affect SERF1B by modifying cytoskeleton dynamics and cell motility, which are processes that could have downstream effects on SERF1B activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Disrupts protein transport by inhibiting the exchange of protein ADP-ribosylation factor 1 (ARF1), potentially leading to mislocalization and functional inhibition of SERF1B if it is dependent on proper intracellular trafficking. | ||||||